These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23098484)

  • 1. Mitochondrial D-Loop polymorphism and microsatellite instability in prostate cancer and benign hyperplasia patients.
    Ashtiani ZO; Heidari M; Hasheminasab SM; Ayati M; Rakhshani N
    Asian Pac J Cancer Prev; 2012; 13(8):3863-8. PubMed ID: 23098484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutathione S-transferase gene variants and risk of benign prostate hyperplasia in a North Indian population.
    Konwar R; Manchanda PK; Chaudhary P; Nayak VL; Singh V; Bid HK
    Asian Pac J Cancer Prev; 2010; 11(2):365-70. PubMed ID: 20843117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
    Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
    Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
    BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
    Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
    Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
    Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
    J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese.
    Hamasaki T; Inatomi H; Katoh T; Ikuyama T; Matsumoto T
    Urol Int; 2002; 68(4):226-31. PubMed ID: 12053022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
    Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
    HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
    Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
    Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population.
    Dargahi Abbasabad G; Banan Khojasteh SM; Eskandari Naji H; Zamani MR; Hajipour H; Serati-Nouri H
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1717-1720. PubMed ID: 29938471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
    Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
    Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
    Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
    Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
    Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
    Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
    Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.